AI Article Synopsis
- * Researchers measured serum Sema4A levels in MG patients with different antibody types and found significantly higher levels in those with acetylcholine receptor (AChR) and muscle-specific tyrosine kinase (MuSK) antibodies compared to healthy controls.
- * There was a correlation between Sema4A levels and both AChR antibody levels and clinical classification in patients with AChR antibody-positive MG, suggesting that elevated Sema4A could indicate T-cell
Article Abstract
Myasthenia gravis (MG) is an autoantibody-mediated disease of the neuromuscular junction. Semaphorin 4A (Sema4A) is involved in the activation of T cells in various inflammatory disorders. In this study, we aimed to investigate whether Sema4A is involved in the pathogenesis of MG. We measured serum Sema4A concentrations in 30 treatment-naïve MG patients with acetylcholine receptor (AChR) antibodies, 7 with muscle-specific tyrosine kinase (MuSK) antibodies and 21 normal controls. As a result, serum Sema4A levels were significantly higher in patients with AChR antibody-positive MG and MuSK antibody-positive MG than in controls (p ≤ 0.0001 for both MG groups). Serum Sema4A levels were correlated with AChR antibody levels (Spearman's ρ = 0.39, p = 0.03) and MG Foundation of America clinical classification classes (Spearman's ρ = 0.38, p = 0.04) in patients with AChR antibody-positive MG. In conclusion, high serum Sema4A levels may reflect T-cell activation, and this molecule could be a potential marker of disease activity in MG.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/sji.13360 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Enzymatic Acrolein Production System and Its Impact on Human Cells.
Chem Res Toxicol
August 2024
Department of Health Sciences and Technology, ETH Zürich, Zurich 8092, Switzerland.
Article Synopsis
- Acrolein is a toxic environmental compound that is also produced by gut microbes, but it quickly dissipates from cell culture media, complicating research on its effects.
- A new biosynthesis system was developed using spermine and calf serum to continuously produce acrolein, while managing hydrogen peroxide byproducts, allowing for better study of acrolein's impact on human cells.
- Experiments showed that human colon cells responded similarly to the biosynthetically produced acrolein and pure acrolein regarding gene expression related to oxidative stress and DNA damage, paving the way for more accurate studies on acrolein exposure.
Markedly upregulated serum semaphorin 4A as a novel activity marker of myasthenia gravis.
Scand J Immunol
May 2024
Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Article Synopsis
- * Researchers measured serum Sema4A levels in MG patients with different antibody types and found significantly higher levels in those with acetylcholine receptor (AChR) and muscle-specific tyrosine kinase (MuSK) antibodies compared to healthy controls.
- * There was a correlation between Sema4A levels and both AChR antibody levels and clinical classification in patients with AChR antibody-positive MG, suggesting that elevated Sema4A could indicate T-cell
Comparison of the efficacy of combined budesonide and fexofenadine versus combined fluticasone propionate and fexofenadine on the expression of class-4 semaphorins and their receptors in the peripheral blood cells of patients with allergic rhinitis.
Heliyon
January 2024
Department of Immunology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Article Synopsis
- This study investigated how two different treatments for allergic rhinitis (AR)—budesonide and fexofenadine (B/F) versus fluticasone propionate and fexofenadine (FP/F)—affect gene expression levels in AR patients.
- Results indicated that the B/F treatment led to increased expression of certain genes related to AR, while FP/F treatment resulted in a significant decrease in the expression of those same genes and an increase in IgE levels.
- Both treatment groups showed a reduction in eosinophil percentages, but overall, the B/F treatment was associated with decreased serum IgE levels, suggesting it may be more effective in managing AR.
Semaphorin 4A as a Potential Biomarker for Diagnosis of Systemic Lupus Erythematosus.
Immunol Invest
January 2023
Department of Clinical Laboratory, Affiliated Hospital of North Sichuan Medical College, NanChong, P.R. China.
Article Synopsis
- Sema4A is an immunoregulatory molecule that may play a significant role in systemic lupus erythematosus (SLE) and its relationship with SLE was investigated.
- The study included blood samples from SLE patients, rheumatoid arthritis patients, and healthy controls, assessing Sema4A expression through flow cytometry and ELISA.
- Results showed elevated levels of soluble Sema4A in SLE patients, with a correlation between Sema4A levels and SLE disease activity, suggesting its potential as a diagnostic biomarker for SLE.
The possible involvement of sema3A and sema4A in the pathogenesis of multiple sclerosis.
Clin Immunol
May 2022
The Proteomic Unit, Bnai-Zion Medical Center, Haifa, Israel; The Rappaport Faculty of Medicine, Technion-Israel Institution of Technology, Haifa, Israel. Electronic address:
Article Synopsis
- Immune semaphorins, specifically sema3A and sema4A, play a significant role in autoimmune diseases, particularly Multiple Sclerosis (MS).
- In MS patients, sema3A expression on T regulatory cells is significantly decreased, while serum levels of sema4A are increased compared to healthy individuals, indicating a dysregulation in these molecules.
- The study suggests that sema3A functions as a regulatory molecule and sema4A as a stimulatory one in the context of MS, highlighting their potential as therapeutic targets for treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!